Evaxion Biotech A/S ADR (EVAX) concluded trading on Thursday at a closing price of $3.64, with 3.6 million shares of worth about $13.11 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -73.48% during that period and on January 23, 2025 the price saw a gain of about 52.94%. Currently the company’s common shares owned by public are about 1.08M shares.
Stock saw a price change of 10.64% in past 5 days and over the past one month there was a price change of -18.21%. Year-to-date (YTD), EVAX shares are showing a performance of -13.89% which decreased to -80.12% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.38 but also hit the highest price of $68.05 during that period. The average intraday trading volume for Evaxion Biotech A/S ADR shares is 90.45K. The stock is currently trading -10.68% below its 20-day simple moving average (SMA20), while that difference is down -39.69% for SMA50 and it goes to -73.12% lower than SMA200.
Evaxion Biotech A/S ADR (NASDAQ: EVAX) currently have 1.08M outstanding shares and institutions hold larger chunk of about 10.14% of that.
The stock has a current market capitalization of $3.93M and its 3Y-monthly beta is at -0.30. It has posted earnings per share of -$14.54 in the same period. It has Quick Ratio of 2.80 while making debt-to-equity ratio of 149.86. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EVAX, volatility over the week remained 33.29% while standing at 17.63% over the month.
Analysts are in expectations that Evaxion Biotech A/S ADR (EVAX) stock would likely to be making an EPS of -0.15 in the current quarter, while forecast for next quarter EPS is -1.35 and it is -2.81 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.15 which is -0.15 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -8.0 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 89.88% while it is estimated to decrease by -91.63% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Ladenburg Thalmann on April 02, 2024 offering a Buy rating for the stock and assigned a target price of $8 to it. Coverage by H.C. Wainwright stated Evaxion Biotech A/S ADR (EVAX) stock as a Buy in their note to investors on February 12, 2024, suggesting a price target of $14 for the stock.
